查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553567

肝炎治療市場規模、佔有率、趨勢分析報告：按疾病、通路、地區、細分市場預測，2024-2030

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

肝炎治療市場的成長與趨勢

Grand View Research, Inc.最新報告顯示，到2030年，全球肝炎治療市場規模預計將達到208.4億美元，預測期內複合年成長率為3.7%。

預計在預測期內推動市場的因素包括肝炎感染數量增加、酒精和藥物消費量增加以及肝炎治療機會的增加。

根據患者患病時間的長短，病毒性肝炎通常分為兩種。如果症狀持續少於6個月，則歸類為急性肝炎，如果症狀持續超過6個月，則歸類為慢性肝炎。 HIV 或 HCV 感染者的性伴侶、受感染血液的接受者、使用注射藥物或鼻腔藥物的患者以及生活在不衛生條件下的人群患肝炎的風險增加。

根據世界衛生組織的基本估計，全世界約有4億人感染至少一種肝炎，每年約有1.4人死於肝炎。政府或私人機構積極進行疫苗接種以預防肝炎的情況很少。與甲型肝炎和乙型肝炎相比，HCV 會引起更嚴重的併發症。根據世界衛生組織估計，全世界每年有 1.5 億人受到C型肝炎感染。此外，大多數感染HCV的人會發展為肝癌或肝硬化，近70萬人死於C型肝炎感染及相關疾病。

肝炎治療市場報告亮點

  • 到2023年，C型肝炎治療將佔據大部分市場佔有率。
  • 2023年，由於意識層級高且擁有先進的醫療基礎設施，北美地區佔據了大部分收益佔有率。
  • 然而，由於醫療保健支出迅速增加，亞太地區在預測期內的複合年成長率預計將達到 6.6%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章肝炎治療市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肝炎治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章肝炎治療市場：依疾病分類的估計與趨勢分析

  • 細分儀表板
  • 肝炎治療市場：2023 年和 2030 年疾病變化分析
  • 甲型肝炎
  • B型肝炎
  • C型肝炎
  • 其他

第5章肝炎治療市場：按分銷管道估計和趨勢分析

  • 細分儀表板
  • 肝炎治療市場：2023 年和 2030 年分銷管道波動分析
  • 醫院藥房
  • 藥局和藥房
  • 其他

第6章 肝炎治療市場：區域估計與趨勢分析

  • 2023 年及 2030 年肝炎治療市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Zydus Group
    • GSK plc.
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Lupin
    • Cipla
簡介目錄
Product Code: GVR-1-68038-449-9

Hepatitis Therapeutics Market Growth & Trends:

The global hepatitis therapeutics market size is expected to reach USD 20.84 billion by 2030, registering a CAGR of 3.7% during the forecast period, according to a new report by Grand View Research, Inc. Few factors that are expected to drive the market over the forecast period include the rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.

Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, the majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Hepatitis Therapeutics Market Report Highlights:

  • Owing to the high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2023
  • In 2023, North American region accounted for the majority of the revenue share, owing to high patient awareness levels and the presence of advanced healthcare infrastructure
  • However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 6.6% over the forecast period owing to rapidly increasing healthcare expenditure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hepatitis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hepatitis Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Hepatitis Therapeutics Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hepatitis Therapeutics Market: Solution Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Hepatitis A
    • 4.3.1. Hepatitis A Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Hepatitis B
    • 4.4.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Hepatitis C
    • 4.5.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hepatitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hepatitis Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hospital Pharmacies
    • 5.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Drug Stores and Retail Pharmacies
    • 5.4.1. Drug Stores and Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hepatitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Hepatitis Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Australia Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. South Korea
      • 6.4.7.1. South Korea Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Hepatitis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Teva Pharmaceutical Industries Ltd.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Zydus Group
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. GSK plc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. AbbVie Inc.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Gilead Sciences, Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Lupin
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Cipla
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives